Journal of Pharmaceutical Investigation

  • 제34권2호
  • /
  • Pages.107-114
  • /
  • 2004
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

프로스타글란딘 E1 에칠에스테르의 외용 리오겔 제제 설계

External Lyogel Formulation of Prostaglandin E1 Ethyl Ester

  • 발행 : 2004.04.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

External lyogels containing prostaglandin $E_1$ ethyl ester $(PGE_1-EE)$, a prodrug of prostaglandin $E_1\;(PGE_1)$ as a therapeutic agent for erectile dysfunction, were formulated to overcome the aqueous instability and enhance the percutaneous absorption. Lyogels of $PGE_1-EE$ were prepared with ethanol (EtOH)/proplyene glycol (PG) cosolvent system as a vehicle, cineol as an enhancer, and hydroxypropylcellusose as a gelling agent. In vitro percutaneous absorption studies were performed to determine the rate of $PGE_1$ absorption through rat or hairless mouse skin. The permeability of $PGE_1-EE$ lyogel with enhancer was 16-fold greater than that of lyogel without enhancer. Cosolvent produced 9-fold increase in percutaneous absorption. Pharmacodynamic effects of lyogels were evaluated in mature male cats in terms of intracavernosal pressure (ICP). Lyogels containing 0.1 % of $PGE_1-EE$ showed higher ICP compared to intraurethral preparation of $PGE_1$ (1 %) and enhancer-free control lyogel. The shelf-life $(t_{10%})$ of lyogel at refrigerated condition $(4^{\circ}C)$ was calculated as 928 days, which is 4.2 times longer than that of control hydrogel. As a result, $PGE_1-EE$ was formulated successfully to a lyogel system with a selective enhancer and cosolvent system for the topical delivery of $PGE_1$.

키워드

참고문헌

  1. NIH Concensus Development Panel on Impotence, NIH Consensus Conference, impotence. JAMA 270, 83-90 (1993)
  2. T.F. Lue, Erectile dysfunction, N. Engl. J. Med., 342, 1802-1813 (2000) https://doi.org/10.1056/NEJM200006153422407
  3. T. Tarcan, K.M. Azadzoi, M.B. Siroky, I. Goldstein and R.J. Krane, Age-related erectile and voiding dysfunction: The role of arterial insufficiency, Br. J. Urol., Suppl., 82, 26-33 (1998) https://doi.org/10.1046/j.1464-410X.1998.0820s1026.x
  4. G. Williams, C.C. Abbou, E.T. Amar, P. Desvaux, T.A. Flam, G.A.B. Lycklama Nijeholt, S.F. Lynch, R.J. Morgan, S.C. M ller, H. Porst, J.P. Pryor, P. Ryan, U.K.F. Witzsch, M.M. Hall, V.A. Place, A.P. Spivack and N. Gesundheit, Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction, Br. J. Urol., 81, 889-894 (1998) https://doi.org/10.1046/j.1464-410x.1998.00703.x
  5. H.A. Feldman, I. Goldstein, D.G. Hatzichristou, R.J. Krane and J.B. Mekinlay, Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study, J. Urol., 151, 54-61 (1991)
  6. J.E. Morlev and F.E. Kaiser, Impotence: the internist's approach to diagnosis and treatment, Adv. Intern. Med., 38, 151-168 (1993)
  7. P.F. Fulgham, J.S. Cochran, J.L. Denman, B.A. Feagins, M.B. Gross, K.T. Kadesky, M.C. Kadesky, A.R. Clark and C.G. Roehrborn, Disappointing initial results with transcurethral alprostadil for erectile dysfunction in a urology practice setting, J. Urol., 160, 2041-2046 (1998) https://doi.org/10.1016/S0022-5347(01)62238-9
  8. R. Virag, Intracavernous injection of papaverine for erectile failure, Letter to the editor, Lancet, 2, 938 (1982)
  9. A.W. Zorgniotti and R.S. Lefleur, Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence, J. Urol., 133, 39-41 (1985) https://doi.org/10.1016/S0022-5347(17)48774-X
  10. F. Montorsi, G. Guazzoni, P. Rigatti and G. Pozza, Pharmacological management of erectile dysfunction, Drugs, 50, 465-479 (1995) https://doi.org/10.2165/00003495-199550030-00005
  11. M. Lakin, The evaluation and nonsurgical managment of impotence, Semin. Nephrol., 14, 544-550 (1994)
  12. E.J. Keogh, Pharmacotherapy for impotence, Current Opinion in Urology, 4, 363-339 (1994)
  13. R.J. Krane, Editorial : Impotence, J. Urol., 153, 1841-1842 (1995)
  14. D.C. Anderson and C.F. Seifert, Topical nitrate treatment of impotence, Ann. Pharmacother., 27, 1203-1205 (1993)
  15. G. Cavallini, Minoxidil versus nitroglycerine : a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence, J. Urol., 146, 50-52 (1991) https://doi.org/10.1016/S0022-5347(17)37712-1
  16. E.D. Kim, E.I. Rashidy and K.T. Macvary, Papaverine topical gel for treatment of erectile dysfunction, J. Urol., 153, 361-365 (1995) https://doi.org/10.1097/00005392-199502000-00019
  17. J. Feenstra, R.J.H.M. van Drie-Pierik, C.F. Lacle and B.H.C. Stricker, Acute myocardial infarction associated with sildenafil, Lancet, 352, 957-958 (1998) https://doi.org/10.1016/S0140-6736(98)00015-4
  18. U. Gresser and C.H. Gleiter, Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil- Review of the literature, Eur. J. Med. Res., 7, 435-446, (2002)
  19. L.S. Palmer, M. Valcic, A. Melman, A. Giraldi, G. Wagner and G.J. Christ, Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells, J. Urol., 152, 1308-1314 (1994) https://doi.org/10.1016/S0022-5347(17)32573-9
  20. N. Ishii, H. Watanabe, C. Irisawa, Y. Kikuchi, S. Kawanura, K. Suzuki, R. Chiba and M. Tokiwa, Studies on male sexual impotence report: Therapeutic trial with prostaglandin $E_{1}$ for organic impotence, Jap. J. Urol., 77, 954-962 (1986) https://doi.org/10.5980/jpnjurol1928.77.6_954
  21. J. Chen, M.F. Godschalk, P.G. Katz, and T. Mulligan, Incidence of penile pain after injection of a new formulation of prostaglandin $E_{1}$, J. Urol., 154, 77-79 (1995) https://doi.org/10.1016/S0022-5347(01)67232-X
  22. P. Schramek, R. Dorninger, M. Waldhauser, P. Konency and P. Porpzczy, Prostaglandin $E_{1}$ in erectile dysfunction: Efficiency and incidence of priapism, Brit. J. Urol., 65, 68-71 (1990) https://doi.org/10.1111/j.1464-410X.1990.tb14664.x
  23. W.W. Kerfoot and C.C. Carson, Pharmacologically induced erections among geriatric men, J. Urol., 146, 1022-1024 (1991) https://doi.org/10.1016/S0022-5347(17)37992-2
  24. M. Waldhauser and P. Schramek, Efficiency and side effect of prostaglandin $E_{1}$ in the treatment of erectile dysfunction, J. Urol., 140, 525-527 (1988) https://doi.org/10.1016/S0022-5347(17)41709-5
  25. M.K. Irwin and E.J. Kata, High attrition rate with intracavernous injection of prostaglandin $E_{1}$ for impotency, Urology, 43, 84-87 (1994) https://doi.org/10.1016/S0090-4295(94)80272-6
  26. J.N. Weiss, G.H. Badlani, R. Ravelli and N. Brettschneider, Reason for high drop out rate with self injection therapy for impotence, Int. J. Impotence Res., 6, 171-174 (1994)
  27. P. Ekman, L. Sj gren, G. Englund and G.E. Persson, Optimizing the therapeutic approach of transurethral alprostadil, BJU Int., 86, 68-74 (2000) https://doi.org/10.1046/j.1464-410x.2000.00723.x
  28. P. Werthman and J. Rajfer, Muse therapy: Preliminary clincal observations, Urology, 50, 809-811 (1997) https://doi.org/10.1016/S0090-4295(97)00448-2
  29. M.T. Sheu, L.H. Lin, B.W. Spur, P.Y.K. Wong and H.S. Chiang, Investigation of the percutaneous penetration of prostaglandin $E_{1}$ and its ethyl ester, J. Controlled Release, 55, 153-160 (1998) https://doi.org/10.1016/S0168-3659(98)00045-5
  30. H.O. Ho, M.C. Hwang, S.L. Tseng, L.H. Lin, K.T. Chen, H.S. Chiang, B.W. Spur, P.Y.K. Wong and M.T. Sheu, The percutaeneous penetration of prostaglandin $E_{1}$ and its alkyl esters, J. Controlled Release, 58, 349-355 (1999) https://doi.org/10.1016/S0168-3659(98)00169-2
  31. H. Adach, T. Irie, F. Hirayama and K. Uekama, Stabilization of prostaglandin $E_{1}$ in fatty alcohol propylene glycol ointment by acidic cyclodextrin derivative O-carboxymethyl-ethyl-$\beta$-cyclodextrin, Chem. Pharm. Bull., 40, 1586-1591 (1992) https://doi.org/10.1248/cpb.40.1586
  32. R.G. Stehle and T.O. Oesterling, Stability of prostaglandin $E_{1}$ and dinoprostone(prostaglandin $E_{2}$) under strongly acidicand basic conditions, J. Pharm. Sci., 62, 1590-1595 (1977)
  33. L.H. Lin, H.O. Ho, K.T. Chen, H.S. Chiang and M.T. Sheu, Stability of prostaglandin $E_{1}$ ethylester, Chin. Pharm. J., 50, 97-105 (1998)
  34. K.K. Levision, K. Takayama, K. lsowa, K. Okabe and T. Nagai, Formulation optimization of indomethacin gels contaning a combination of three kinds of cyclic monoterpenes as percutaneous penetraton enhancer, J. Pharm. Sci., 83, 1367-1372 (1994) https://doi.org/10.1002/jps.2600830932
  35. H. Okabe, K Takayama and T. Nagai, Percutaneous absorption of ketoprofen from acrylic gel patches containing d-limonene and ethanol as absroption enhancer, Chem. Pharm. Bull., 40, 1906-1910 (1992) https://doi.org/10.1248/cpb.40.1906
  36. A.C. Williams and B.W. Barry, Terpenes and the lipid-protein-partitioning theory of skin penetraton enhancement, Pharm. Res., 8, 17-24 (1991) https://doi.org/10.1023/A:1015813803205
  37. Y. Obata, K. Takayama, Y. Machida and T. Nagai, Combined effect of cyclic monoterpenes and ethanol on percutaneous absorption of diclofenac sodium, Drug Design Del., 8, 137-144 (1991)
  38. D. Kobayash, T. Matsuzawa, K. Sugibayashi, Y. Morimoto, M. Kobayashi and M. Kimura, Feasibility of use of several cardiovascular agents in transdermal therapeutic systems with l-menthol-ethanol system on hairless rat and human skin, BioI. Pharm. Bull., 16, 254-258 (1993) https://doi.org/10.1248/bpb.16.254
  39. M.A. Yamane, A.C. Williams and B.W. Barry, Terpene penetration enhancer in propylene glycol/water cosolvent systems: effectiveness and mechanism of action, J. Pharm. Pharmacal., 47, 978-989 (1995) https://doi.org/10.1111/j.2042-7158.1995.tb03282.x
  40. J.Y. Fang, C.T. Kuo, Y.B. Huang, P.C. Wu and Y.H. Tsai, Transdermal delivery of sodium nonivamide acetate from volatile vehicles: effects of polymers, Int. J. Pharm., 176, 157-167 (1999)